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Abstract
PTEN loss has been associated with poorer prognosis in many solid tumors. However, such investigation in
lymphomas is limited. In this study, PTEN cytoplasmic and nuclear expression, PTEN gene deletion, and PTEN
mutations were evaluated in two independent cohorts of diffuse large B-cell lymphoma (DLBCL). Cytoplasmic
PTEN expression was found in approximately 67% of total 747 DLBCL cases, more frequently in the activated B-
cell–like subtype. Nuclear PTEN expression was less frequent and at lower levels, which significantly correlated
with higher PTEN mRNA expression. Remarkably, loss of PTEN protein expression was associated with poorer
survival only in DLBCL with AKT hyperactivation. In contrast, high PTEN expression was associated with Myc
expression and poorer survival in cases without abnormal AKT activation. Genetic and epigenetic mechanisms for
loss of PTEN expression were investigated. PTEN deletions (mostly heterozygous) were detected in 11.3% of
DLBCL, and showed opposite prognostic effects in patients with AKT hyperactivation and in MYC rearranged
DLBCL patients. PTEN mutations, detected in 10.6% of patients, were associated with upregulation of genes
involved in central nervous system function, metabolism, and AKT/mTOR signaling regulation. Loss of PTEN
cytoplasmic expression was also associated with TP53 mutations, higher PTEN-targeting microRNA expression,
and lower PD-L1 expression. Remarkably, low PTEN mRNA expression was associated with down-regulation of a
group of genes involved in immune responses and B-cell development/differentiation, and poorer survival in
DLBCL independent of AKT activation. Collectively, multi-levels of PTEN abnormalities and dysregulation may play
important roles in PTEN expression and loss, and that loss of PTEN tumor-suppressor function contributes to the
poor survival of DLBCL patients with AKT hyperactivation.
Neoplasia (2018) 20, 574–593
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iffuse large B-cell lymphoma (DLBCL) is the most common and
terogeneous type of B-cell lymphoma.Gene expression profiling (GEP)
s classified DLBCL into twomolecularly distinctive subtypes: germinal
nter B-cell–like (GCB) and activated B-cell–like (ABC) types, with
ne expression profiles resembling those of normal germinal center B
lls and those of mitogenically activated blood B cells, respectively [1].
The current standard regimen of rituximab, cyclophosphamide,
xorubicin, vincristine, and prednisone (R-CHOP) has clearly
proved the outcome of DLBCL patients over the past decades [2],
t because some patients with refractory disease or with early relapse
ill have worse outcomes [3], further clarification of disease subgroups
ith distinct pathology mechanisms is needed. Recent studies showed
at the phosphatidylinositol-3 kinase (PI3K)-AKT pathway was
nstitutively activated in 25-52% of DLBCL [4,5], which prompted
to study the significance of PTEN (phosphatase and tensin
mologue), a major negative regulator of the PI3K/AKT signaling, in
e pathogenesis of DLBCL. PTEN antagonizes PI3K signaling
rough dephosphorylation of phosphoinositide-3-phosphate (PIP3).
EN deficiency leads to PIP3 accumulation and thereby de-
pression of the PI3K/AKT pathway, which in turn promotes cell
owth, proliferation, angiogenesis, and other cellular processes [6].
The phosphatase activities of PTEN in the plasma membrane are
ely regulated by complex mechanisms. Dynamic PTEN binding to
e plasma membrane, as a critical step for PI3K signaling inhibition by
EN, is determined by local PIP2 and PIP3 gradients [7,8] and PTEN
nformation which is regulated by posttranslational modifications such
phosphorylation, ubiquitination, acetylation, and SUMOylation.
osphorylation of the C-terminal tail prevents PTEN from membrane
nding and keeps PTEN inactive in the cytoplasm [8,9].PTEN localizes not only to the cytoplasm but also to the nucleus
d other subcellular compartments [8]. PTEN localized in the
cleus has tumor-suppressive functions in maintaining chromo-
mal stability by up-regulation of RAD51 and interaction with p53
omoting p300-mediated p53 acetylation, independent of its
zymatic activities against the PI3K/AKT pathway [10]. Several
gulatory mechanisms for PTEN nuclear localization have been
oposed, including passive diffusion, active transport mediated by
ajor vault protein, nuclear localization signal, interaction with
TPase Ran, and monoubiquitination of PTEN [8,11,12].
Loss of PTEN function is significantly related to advanced disease,
emotherapy resistance, and poor survival in patients with prostate,
east, melanoma, colorectral, esophageal, and head and neck cancers
3–20]. PTEN can be inactivated by genetic and epigenetic
echanisms. PTEN is one of the most frequently mutated genes,
d PTEN gene alterations play critical roles in the pathogenesis of
any human cancers [21–25]. In DLBCL, Lenz and colleagues
und that PTEN gene deletion was associated with the GCB subtype
6]; Pfeifer et al demonstrated that absence of PTEN expression
fines a PI3K/AKT-dependent GCB-DLBCL subtype in both cell
es and primary samples [27]. However, a few studies have
ggested different prognostic effects of PTEN loss/expression in
all DLBCL cohorts [28–31]. Large-scale studies are needed to
tablish the clinical significance of PTEN expression/loss and genetic
normalities in DLBCL.
In this study, we analyzed cytoplasmic and nuclear expression of
EN protein, PTEN deletions, and PTEN mutations and their
ognostic significance in a large number of patients with de novo
LBCL treated with R-CHOP, and explored the potential regulatory
echanisms for PTEN deficiency in DLBCL.
MP
R
ac
di
an
ly
cu
im
PT
ad
in
as
ph
ev
ca
im
P
re
em
ce
st
0
20
40
60
80
100
0 10 20 30 40 50 60 70 80 90 100
0
20
40
60
80
100
PTEN+ GCBGCB ABC PTEN+ ABC
+ +
A
B
D
C
E
F
PD-L1+ DLBCL
G
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
+
0
20
40
60
80
100
n=18 n=87
Figure 1. Analysis of PTEN expression by immunohistochemistry (IHC). (A) Representative hematoxylin and eosin and immunohisto-
chemistry of PTEN expression in GCB-DLBCL and ABC-DLBCL. (B and C) Histograms and comparison of cytoplasmic (Cyto-) and nuclear
(Nuc-) PTEN expression in DLBCL and between GCB/ABC subtypes (training cohort). (D) Cytoplasmic PTEN expression was associated
with higher nuclear PTEN expression in both GCB-DLBCL and ABC-DLBCL. (E) Cytoplasmic PTEN expression was associated with higher
p-AKT expression in GCB-DLBCL and ABC-DLBCL, and inversely associated with survivin expression in ABC-DLBCL. (F) Representative
hematoxylin and eosin and immunohistochemistry of PD-L1 expression in DLBCL. The ABC compared with the GCB subtype had a
significantly higher mean level of PD-L1 expression. Cytoplasmic PTEN expression was associated with a higher mean level of PD-L1
expression in overall DLBCL and in cases with high p-AKT expression. (G) Cytoplasmic PTEN expression was associated with higher mean
levels of Myc, p-STAT3, PI3K, MDM2, and p21 expression in DLBCL. Significant P values are in bold.
576 PTEN expression and deficiency in DLBCL Wang et al. Neoplasia Vol. 20, No. 6, 2018aterials and Methods
atients
Patients were organized as a part of the International DLBCL
ituximab-CHOP Consortium Program study, and were selected
cording to the eligibility and exclusion criteria (fulfilling the DLBCL
agnostic criteria and treated with R-CHOP or R-CHOP–like therapy,
d excluding patients with transformation from lower grade B-cell
mphoma, primary mediastinal large B-cell lymphoma, primary
taneous DLBCL, primary central nervous system DLBCL, or acquired
munodeficiency) which have been described previously [32,33].
EN staining was achieved initially in 478 cases (training cohort) and
ditionally in 269 cases, a later assembled validation cohort. Thestitutional review boards of each participating center approved this study
being of minimal to no risk or as exempt. Nuclear expression of
ospho-AKT-Ser473 (p-AKT, activated form of AKT) has been
aluated in the training cohort [34] and data were available in 461
ses. Cell-of-origin classification was according to GEP and/or
munohistochemistry (IHC) algorithms as described previously [32,35].
TEN and PD-L1 Immunohistochemistry
Hematoxylin and eosin–stained slides from DLBCL cases were
viewed, and representative areas of the formalin-fixed and paraffin-
bedded (FFPE) tissue sections with the highest percentages of tumor
lls were selected for tissuemicroarray construction and subject for IHC
aining. PTEN expression was evaluated by IHC using a PTEN
Table 1. Comparison of clinical and molecular features of patients with diffuse large B-cell lymphoma (DLBCL) with and without PTEN cytoplasmic expression in the training cohort
in DLBCL in GCB-DLBCL in ABC-DLBCL in p-AKThigh DLBCL
Cytoplasmic
PTEN+
Cytoplasmic
PTEN¯
Cytoplasmic
PTEN+
Cytoplasmic
PTEN¯
Cytoplasmic
PTEN+
Cytoplasmic
PTEN¯
Cytoplasmic
PTEN+
Cytoplasmic
PTEN¯
n=306 n=172 P n=137 n=101 P n=165 n=69 P n=89 n=18 P
GCB/ABC Subtype
GCB 137 101 .004 41 12 .13
ABC 165 69 48 6
Age, years
b 60 128 76 .63 70 52 1.0 55 22 .88 44 9 1.0
≥ 60 178 96 67 49 110 47 45 9
Sex
Male 190 92 .081 86 55 .23 102 37 .25 56 8 .19
Female 116 80 51 46 63 32 33 10
Stage
I - II 134 85 .21 72 56 .42 60 27 .88 39 5 .41
III - IV 164 80 63 39 99 41 47 11
B-symptoms
No 190 103 .92 95 61 .38 92 40 .88 57 9 .57
Yes 103 57 37 31 65 26 29 7
LDH
Normal 109 51 .12 52 31 .26 56 20 .29 30 4 .28
Elevated 169 110 73 61 93 47 48 14
Extranodal sites
0 - 1 227 126 .64 107 74 1.0 117 51 .74 64 8 .067
≥ 2 71 35 27 18 43 16 21 8
ECOG score
0 - 1 230 124 .89 105 71 1.0 121 51 .71 65 10 .47
≥ 2 46 26 18 12 28 14 15 4
Tumor size
b 5 cm 135 67 .73 62 40 1.0 71 26 .73 35 2 .035
≥ 5 cm 95 51 43 29 52 22 23 8
IPI score
0 - 2 182 101 .76 92 64 1.0 86 35 .89 51 6 .11
N 2 118 61 43 29 75 32 36 11
Therapy response
CR 237 120 .079 105 72 .37 128 46 .10 65 11 .39
PR 35 29 12 16 23 13 13 4
SD 11 11 7 6 4 5 7 0
PD 23 12 13 7 10 5 4 3
Nuclear PTEN expression
0% 69 129 b .0001 30 72 b .0001 39 55 b .0001. 25 13 .0008
N 0% 237 43 107 29 126 14 64 5
TP53 mutations
No 214 115 .044 90 67 .41 121 46 .065 62 13 .81
Yes 51 44 28 27 23 17 12 3
MDM2 expression
≤ 10% 169 119 .001 82 72 .03 86 47 .022 53 10 .75
N 10% 131 47 54 25 77 21 36 8
BCL6 expression
≤ 30% 62 47 .05 12 16 .07 50 31 .025 16 2 .58
N 30% 237 116 124 80 113 36 72 14
BLIMP-1 expression
b 5% 173 116 .033 94 77 .24 78 39 .32 44 15 .017
≥ 5% 118 51 37 21 80 30 43 3
IgA IHC
0% 302 163 .011 134 96 .24 164 65 .012 89 17 .026
100% 4 9 3 5 1 4 0 1
IgG IHC
0% 282 146 .013 126 88 .22 152 56 .015 82 17 .73
100% 24 26 11 13 13 13 7 1
PD-L1 IHC
b 5% 50 48 .003 33 43 .0045 17 5 .62 14 7 .047
≥ 5% 244 117 99 56 142 60 73 11
Abbreviations: LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; CR, complete remission; PR, partial response; SD, stable disease; PD,
progressive disease; GCB, germinal center B-cell–like; ABC, activated B-cell–like. Significant P values are highlighted in bold.
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578 PTEN expression and deficiency in DLBCL Wang et al. Neoplasia Vol. 20, No. 6, 2018tibody (138G6, Cell Signaling). PTEN expression was analyzed for
sitive versus negative (i.e., loss of) expression status, as well as high
rsus low expression. The cutoff used for high cytoplasmic PTEN
pression was N40% and the cutoff for high nuclear PTEN expression
as N30% of tumor cells, which were determined by the X-tile software
ale School of Medicine, New Haven, CT).
Expression of p-AKT, IL-6, PI3K [34], Myc [36], p-STAT3 [37],
DM2 [38], p21 [39], BLIMP-1 [40], IgA and IgG [41] had been
sessed by previous studies; the cutoff for p-AKThigh expression
KT hyperactivation) was ≥70% as described previously [34].
PD-L1 expression was assessed by IHC using a DAKO PD-L1
tibody. The IHC results were scored independently by three
thologists (J.K., Y.X, and K.H.Y), and final scores were based on
nsensus. The cutoff for PD-L1 positivity is ≥5% of tumor cells.
luorescence in situ Hybridization and Gene Sequencing
Fluorescence in situ hybridization (FISH) analysis was performed
d data were available for 359 cases of the training cohort and 248
ses of the validation cohort. To evaluate PTEN gene (chromosome
p13.1) deletions, a commercial PTEN probe was utilized (Zyto-
ight® SPEC PTEN/CEN 10 Dual Color Probe Z-2078-200;
ytovision, Bremerhaven, Germany). The ratio of PTEN signals
reen) to CEP10 signals (red) was counted in 200 tumor cells. If this
tio was lower than 0.81, heterozygous PTEN deletion was
nsidered to be present. Ratios lower than 0.46 were considered
be suggestive of homozygous deletions. The ratios were calculated
ratios below the mean plus three standard deviations of green to red
gnal ratios in reference cases (5 tonsils) and subtraction of tumor-
filtrating T cells, which accounted for 15% of undeleted alleles.
For PTEN sequencing, genomic DNA was extracted from FFPE
ssues of 368 cases and then subjected to Sanger sequencing. The
quencing results were compared to the National Center for
iotechnology Information (NCBI) reference sequence
M_000314 (PTEN) to identify non-synonymous PTEN muta-
ons. Single nucleotide polymorphisms documented by the NCBI
SNP database (build 147) have been excluded.
ene Expression Profiling and microRNA Profiling
Gene expression profiling was performed by using the Affymetrix
eneChip Human Genome HG-U133 Plus Version 2.0 Array as
scribed previously (GSE31312) [32,42]. Microarray data were normal-
ed for further supervised clustering analysis. Multiple t-tests were used to
entify differentially expressed genes between groups with and without
EN abnormalities, and the P values obtained were corrected for the
lse discovery rate (FDR) using the beta-uniform mixture method.
microRNA (miRNA) profiling was performed by HTG Molecular
iagnostics Inc. (Tucson, AZ) using FFPE tissue sections (unpub-
hed preliminary data). miRNAs targeting PTEN are according to the
erature review [43] and TargetScan: http://www.targetscan.org).co
ex
(a
(F
co
P
ex
mtatistical Analysis
The clinical and pathological features of DLBCL patients were
mpared using the Fisher’s exact or chi-square test. The unpaired t-
st (2-tailed) was used to compare mean expression levels of
omarkers between DLBCL groups. Overall survival (OS) was
lculated from time of diagnosis to last follow-up or death due to any
use. Progression-free survival (PFS) was calculated from time of
agnosis to disease progression, relapse, or death from any cause.atients who were alive and free of disease progression at last follow-
were censored. Survival analysis was performed using the Kaplan-
eier method with the Prism 5 program (GraphPad Software, San
iego, CA), and differences in survival were compared using the log-
nk (Mantel-Cox) test. Multivariate survival analysis was performed
ing a Cox proportional hazards regression model with the SPSS
ftware program (version 19.0; IBMCorporation, Armonk, NY). All
fferences with P ≤ .05 were considered statistically significant.
esults
TEN is Expressed in Both Cytoplasm and Nucleus and
e Cytoplasmic Expression is More Frequently Lost in GCB-
LBCL
In view of PTEN’s distinct functions in the cytoplasm and nucleus,
e evaluated PTEN expression in the cytoplasm and nucleus
mpartments separately. Representative PTEN+ IHC staining
d the expression histogram for the training cohort are shown in
igure 1, A and B. We found cytoplasmic PTEN expression was
gnificantly higher than that in the nuclei (Figure 1C). Expression of
toplasmic PTEN (Cyto-PTEN+) was observed in 306 (64%) of
8 DLBCL in the training cohort, and showed significant
fferences between GCB and ABC subtypes: 57.6% (137/238) of
CB-DLBCL versus 70.5% (165/234) of ABC-DLBCL (P = .004,
able 1). The mean level of Cyto-PTEN expression for GCB-
LBCL was also significantly lower than that for ABC-DLBCL
igure 1C). On the other hand, nuclear expression of PTEN (Nuc-
TEN+) was observed in 280 (58.6%) of 478 DLBCL, including
.1% (136/238) of GCB-DLBCL and 59.8% (140/234) of ABC-
LBCL. In contrast with the higher cytoplasmic PTEN expression in
BC-DLBCL, there was a trend of higher nuclear PTEN expression
GCB than in ABC DLBCL (P = .072, Figure 1C), although
clear PTEN expression significantly correlated with cytoplasmic
TEN expression (Table 1, Figure 1D). Regardless of the expression
mpartments, totally 129 (26.7%) of 478 DLBCL did not have any
TEN expression (Cyto-PTEN− and Nuc-PTEN−).
To validate the results, we assembled an independent DLBCL cohort
= 204). Compared with the training cohort, the validation cohort
owed a similar pattern of PTEN expression, with a slightly lower
equency of Cyto-PTEN loss, whereas a higher frequency of Nuc-PTEN
ss compared with the training cohort: 25% of DLBCLs were Cyto-
EN−, and 69% of DLBCLs were Nuc-PTEN−; 11% of DLBCLs did
t show either cytoplasmic or nuclear PTEN expression. Consistent
ith the results in the training cohort, in the validation cohort cytoplasmic
pression is predominant and the cytoplasmic PTEN and nuclear PTEN
pression are significantly correlated (Supplementary Figure S1A).
Surprisingly, PTEN expression (cytoplasmic and/or nuclear) was
sociated with a higher mean level of phospho-AKT-Ser473
otein (p-AKT) nuclear expression but not AKT1 mRNA expression
igure 1E and Supplementary Figure S1A for the training and validation
hort, respectively). However, Cyto-PTEN+ (but not Nuc-PTEN+)
pression was associated with significantly decreased survivin expression
downstream target of the PI3K/AKT pathway [44]) in ABC-DLBCL
igure 1E) independent of TP53mutation status, which may suggest a
rrelation between PTEN expression and decreased AKT function.
Cyto-PTEN+ expression, but not p-AKThigh, PI3Khigh, or Nuc-
TEN+ expression, showed significant association with PD-L1
pression, which is considered as a tumor immune evasion
echanism of DLBCL [45] (Table 1, Figure 1F). Conversely,
P
L
ex
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)shtnom(emiT)shtnom(emiT
E
Figure 2. Survival analysis for PTEN expression/loss in DLBCL with high phosphorylated-AKT expression (p-AKThigh, cutoff: ≥70%). (A)
Loss of PTEN cytoplasmic expression was associated with significantly poorer overall survival rate (OS) in patients with high p-AKT
expression, especially in GCB-DLBCL. (B) Loss of PTEN nuclear expression was associated with decreased progression-free survival rate
(PFS) in GCB-DLBCL patients with high p-AKT expression. This effect was only significant in the group with an International Prognostic
Index (IPI) score≤2. (C) Survival analysis in respect to both cytoplasmic and nuclear PTEN+ status in patients with p-AKThigh GCB-DLBCL.
(D) In GCB-DLBCL cases with cytoplasmic PTEN expression, p-AKT expression level was not prognostic. (E) In GCB-DLBCL patients
without cytoplasmic/nuclear PTEN expression, p-AKThigh expression was associated with significantly poorer survival.
Neoplasia Vol. 20, No. 6, 2018 PTEN expression and deficiency in DLBCL Wang et al. 579D-L1+ cases had a higher mean level of PTEN expression than PD-
1− cases (P = .0015). Like Cyto-PTEN expression, PD-L1
pression was significantly higher in the ABC subtype (Figure). Cyto-PTEN+ status was also associated with significantly
gher mean levels of Myc, p-STAT3, PI3K, MDM2, and p21/
DKN1A expression (Figure 1G).
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Ta le 2. Comparison of clinicopathologic features of patients with p-AKT overexpressing diffuse large B-cell lymphoma (DLBCL) respective to the status of cytoplasmic or nuclear PTEN expression,
PT N deletion, and PTEN mutation in the training cohort
p-AKThigh GCB p-AKThigh GCB p-AKThigh DLBCL p-AKThigh DLBCL
Cyto-PTEN+ Cyto-PTEN¯ Nuc-PTEN+ Nuc-PTEN¯ PTEN deletion No PTEN deletion MUT-PTEN WT-PTEN
N (%) N (%) P N (%) N (%) P N (%) N (%) P N (%) N (%) P
Va ables 41 (100) 12 (100) 33 (100) 20 (100) 7 (100) 75 (100) 9 (100) 74 (100)
Ag years
b 24 (58.5) 8 (66.7) .74 20 (60.6) 12 (60.0) 1.0 3 (42.9) 32 (42.7) 1.0 3 (33.3) 40 (54.1) .3
≥ 17 (41.5) 4 (33.3) 13 (39.4) 8 (40.0) 4 (57.1) 43 (57.3) 6 (66.7) 34 (45.9)
Se
M 29 (70.7) 5 (41.7) .09 24 (72.7) 10 (50.0) .14 4 (57.1) 45 (60.0) 1.0 7 (77.8) 45 (60.8) .47
Fe ale 12 (29.3) 7 (58.3) 9 (27.3) 10 (50.0) 3 (42.9) 30 (40.0) 2 (22.2) 29 (39.2)
St e
I-I 21 (52.5) 3 (30.0) .29 17 (53.1) 7 (38.9) .39 2 (28.6) 27 (39.1) .7 2 (25.0) 26 (36.6) .71
III V 19 (47.5) 7 (70.0) 15 (46.9) 11 (61.1) 5 (71.4) 42 (60.9) 6 (75.0) 45 (63.4)
B mptoms
N 33 (82.5) 7 (70.0) .4 28 (84.8) 12 (70.6) .28 4 (57.1) 44 (62.0) 1.0 5 (71.4) 46 (64.8) 1.0
Ye 7 (17.5) 3 (30.0) 5 (15.2) 5 (29.4) 3 (42.9) 27 (38.0) 2 (28.6) 25 (35.2)
LD
N mal 14 (38.9) 2 (16.7) .29 13 (46.4) 3 (15.0) .031 3 (42.9) 31 (47.7) 1.0 2 (25.0) 27 (42.2) .46
El ated 22 (61.1) 10 (83.3) 15 (53.6) 17 (85.0) 4 (57.1) 34 (52.3) 6 (75.0) 37 (57.8)
Ex anodal sites
0 33 (82.5) 5 (50.0) .046 28 (87.5) 10 (55.6) .017 5 (71.4) 45 (66.2) 1.0 4 (44.4) 48 (70.6) .26
≥ 7 (17.5) 5 (50.0) 4 (12.5) 8 (44.4) 2 (28.6) 23 (33.8) 5 (55.6) 20 (29.4)
EC G score
0 31 (83.8) 6 (75.0) .62 25 (89.3) 12 (70.6) .23 6 (85.7) 50 (82.0) 1.0 6 (85.7) 52 (78.8) 1.0
≥ 6 (16.2) 2 (25.0) 3 (10.7) 5 (29.4) 1 (14.3) 11 (18.0) 1 (14.3) 14 (21.2)
Tu or size
b cm 14 (53.8) 1 (16.7) .18 12 (52.2) 3 (33.3) .44 3 (50.0) 35 (58.3) .69 2 (66.7) 31 (60.8) 1.0
≥ cm 12 (46.2) 5 (83.3) 11 (47.8) 6 (66.7) 3 (50.0) 25 (41.7) 1 (33.3) 20 (39.2)
IP score
0 28 (68.3) 4 (36.4) .081 25 (75.8) 7 (36.8) .008 4 (57.1) 38 (52.8) 1.0 2 (25.0) 42 (58.3) .13
3 13 (31.7) 7 (63.6) 8 (24.2) 12 (63.2) 3 (42.9) 34 (47.2) 6 (75.0) 30 (41.7)
Th rapy response
CR 29 (70.7) 7 (58.3) 1.0 24 (72.7) 12 (60.0) .38 7 (100) 54 (72.0) .18 4 (44.4) 56 (75.7) .11
PR 4 3 2 5 0 12 4 10
SD 4 0 3 1 0 3 0 5
PD 4 2 4 2 0 6 1 3
TP 3 mutations
N 26 (78.8) 8 (72.7) .69 23 (79.3) 11 (73.3) .71 4 (57.1) 64 (88.9) .02 7 (77.8) 59 (86.8) .61
Ye 7 (21.2) 3 (27.3) 6 (20.7) 4 (26.7) 3 (42.9) 8 (11.1) 2 (22.2) 9 (13.2)
PD L1 IHC
b 9 (22.5) 7 (58.3) .031 10 (31.3) 6 (30) 1.0 0 (0) 15 (22.7) .33 13 (19.7) 2 (22.2) 1.0
≥ 31 (77.5) 5 (41.7) 22 (68.8) 14 (70) 6 (100) 51 (77.3) 53 (80.3) 7 (77.8)
Ab reviations: Cyto-PTEN, cytoplasmic PTEN expression; Nuc-PTEN, nuclear PTEN expression; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; IPI, International
Pr nostic Index; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease; GCB, germinal-center B-cell–like; MUT, mutated, WT, wild-type.
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anbsence of PTEN Expression is Associated with Unfavorable
linical Features and Outcomes Only in DLBCL with AKT
yperactivation
Clinical features for PTEN+ and PTEN− DLBCL groups are
own in Table 1 (cytoplasmic expression) and Supplementary Table
(nuclear expression). Cyto-PTEN− expression was not significantly
sociated with any clinical parameters (only trend ofmore female sex).
uc-PTEN− status was associated with elevated serum lactate
hydrogenase (LDH) level (P b .0001). In the DLBCL subset with
AKT hyperactivation (p-AKThigh) [34], Cyto-PTEN− status was
sociated with a larger tumor size (P = .035), and Nuc-PTEN− status
as associated with elevated LDH, extranodal sites N1, ECOG
rformance status N1, tumor size ≥5cm, and International Prognostic
dex (IPI) score N2.Neither cytoplasmic nor nuclear PTEN+ status showed significant
ognostic impact in overall DLBCL. However, Cyto-PTEN− status
as associated with a lower complete remission rate, with a trend of
gnificance in the overall DLBCL cohort (P = .079), and significantly in
e p-AKThigh ABC-DLBCL subset (P = .0007, Table 1). In p-AKThigh
LBCL, Cyto-PTEN− status was associated with lower mean levels of
AKT (P = .042) and PD-L1 expression (P = .042, Figure 1F), but with
gher frequency of survivin expression (26% vs. 8.9%, P = .031) and
gnificantly poorer OS (P = .048), particularly in the GCB subtype (P =
054) (Figure 2A). Moreover, in p-AKThigh GCB-DLBCL, loss of
clear PTEN expression was associated with poorer PFS with
rderline significance (P = .06, Figure 2B), although it was associated
ith significantly lower mean levels of antiapoptotic Bcl-2 (P = .0068)
d MDM2 (P = .0011) expression.
ha
.0
th
PT
an
PF
su
ha
pa
m
G
PT
O
0.
ad
C
PF
bu
su
si
A
an
ex
w
fo
D
bu
Ta
mu
≤3
Va
In
IP
Fe
Tu
B-
*N
In
IP
Fe
Tu
B-
*C
In
IP
Fe
Tu
B-
*N
M
In
IP
Fe
Tu
B-
*C
In
IP
Fe
Tu
B-
*C
M
In
IP
Fe
Tu
B-
*P
*P
Ab
co
In
*
PT
Neoplasia Vol. 20, No. 6, 2018 PTEN expression and deficiency in DLBCL Wang et al. 581Notably, patients with Nuc-PTEN− GCB-DLBCL more frequently
d IPI N2, extranodal sites N1, and elevated LDH (P = .008, .017, and
31, respectively) (Table 2). To eliminate the confounding effects by
ese unfavorable clinical factors, we further compared survival of Nuc-
EN+ and Nuc-PTEN− patients with high and low IPI individually,
d found that Nuc-PTEN− status was associated with markedly shorter
S durations only for patients with an IPI ≤2 (P = .0002, Figure 2B).
Incorporating both cytoplasmic and nuclear PTEN+ status in the
rvival analysis found Cyto-PTEN but not Nuc-PTEN expression
d significant prognostic impact in p-AKThigh GCB-DLBCL
tients (Figure 2C). However, the significance was lost in
ultivariate survival analysis adjusting clinical factors in p-AKThigh
CB-DLBCL. In contrast, in p-AKThigh ABC-DLBCL, Nuc-
EN+ expression was an independent prognostic factor for better
S (P = .003; hazard ratio [HR] 0.16; 95% confidence interval [CI].1
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ble 3. Multivariate analysis for PTEN expression (positive or high), PTEN deletion and PTEN
tations in overall DLBCL, cases with ≥70% p-AKT expression (p-AKThigh), and cases with
0% p-AKT expression (p-AKT−)
OS PFS
riables HR 95% CI P HR 95% CI P
p-AKThigh ABC-DLBCL
I N2 3.28 1.02-10.48 .046 3.84 1.20-12.33 .024
male .27 .096- .74 .011 .34 .13- .89 .028
mor size N5cm 1.91 .67-5.49 .23 1.94 .71-5.28 .19
symptoms 10.2 2.67-39.02 .001 6.37 1.88-21.56 .003
uclear PTEN+ .16 .049- .53 .003 .22 .07- .67 .008
p-AKThigh ABC-DLBCL
I N2 3.84 1.20-12.33 .024 2.35 .85-6.51 .10
male .19 .063- .60 .004 .28 .10- .79 .016
mor size N5cm 2.10 .73-6.09 .17 2.12 .79-5.71 .14
symptoms 7.27 1.88-28.17 .004 4.42 1.37-14.29 .013
ytoplasmic PTEN+ .47 .12-1.77 .26 .53 .14-1.95 .34
overall DLBCL
I N2 2.31 1.63-3.28 b .001 2.28 1.64-3.18 b .001
male .75 .52-1.07 .12 .72 .51-1.02 .064
mor size N5cm 1.15 .80-1.64 .45 1.12 .79-1.57 .53
symptoms 1.62 1.12-2.33 .01 1.59 1.12-2.26 .009
uclear PTENhigh .39 .16- .97 .043 .34 .14- .84 .02
ychigh 2.15 1.49-3.09 b .001 2.10 1.48-2.97 b .001
overall DLBCL
I N2 2.38 1.68-3.38 b .001 2.34 1.67-3.26 b .001
male .86 .60-1.23 .40 .84 .60-1.19 .33
mor size N5cm 1.36 .96-1.92 .084 1.31 .94-1.82 .11
symptoms 1.41 .98-2.03 .063 1.39 .98-1.98 .061
ytoplasmic PTENhigh 1.19 .84-1.69 .33 1.42 1.02-1.98 0.036
p-AKT− DLBCL
I N2 2.59 1.65-4.05 b .001 2.80 1.81-4.32 b .001
male .95 .60-1.49 .82 .85 .54-1.32 .47
mor size N5cm 1.07 .68-1.69 .77 1.03 .67-1.59 .89
symptoms .97 .61-1.56 .90 1.00 .64-1.57 .99
ytoplasmic PTENhigh 1.33 .84-2.09 .22 1.62 1.05-2.50 .03
ychigh 1.71 1.05-2.79 .03 1.63 1.02-2.61 .041
p-AKThigh DLBCL
I N2 4.80 1.78-12.98 .002 3.47 1.51-7.96 .003
male .48 .21-1.07 .072 .34 .15- .78 .011
mor size N5cm 1.38 .63-3.02 .43 1.72 .80-3.71 .17
symptoms 2.59 1.12-5.98 .026 3.07 1.36-6.94 .007
TEN deletion 4.53 .98-20.89 .052 5.30 .99-28.33 .051
TEN mutation 4.53 .97-21.12 .054 3.78 1.02-13.97 .046
breviations: OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI,
nfidence interval; GCB, germinal center B-cell–like; ABC, activated B-cell–like; IPI,
ternational Prognostic Index.
Data for PTEN factors are highlighted in bold. Cutoffs for Nuclear PTENhigh and Cytoplasmic
ENhigh: N30% and N40%, respectively.049-0.53) and PFS (P = .008; HR 0.22; 95% CI 0.07-0.67) after
justing clinical factors (Table 3). In the validation cohort, loss of
yto-PTEN expression was also associated with signficantly shorter
S in p-AKThigh DLBCL (P = .029, Supplementary Figure S1B)
t not in the overall DLBCL cohort. However, in the multivariate
rvival analysis adjusting for clinical factors, Cyto-PTEN− status lost
gnficance as an independent prognostic factor in the validation p-
KThigh DLBCL cohort (data not shown).
Consistent with the role of PTEN in suppressing AKT activation
d activity, the adverse prognostic significance of p-AKThigh
pression in GCB-DLBCL that we have reported previously [34]
as only significant in the Cyto-PTEN− GCB-DLBCL (P = .0022
r OS and P = .0029 for PFS, respectively) and Nuc-PTEN− GCB-
LBCL subsets (P = .12 for OS and P = .0002 for PFS, respectively),
t not in the Cyto-PTEN+ GCB-DLBCL (P = .63 for OS and P =
8 for PFS, respectively) or Nuc-PTEN+ GCB-DLBCL subset (P =
9 for OS and P = .50 for PFS, respectively) (Figure 2, D and E and
pplementary Figure S2).
igh Cytoplasmic PTEN Expression is Associated with Poorer
rvival Only in DLBCL Patients with Low AKT Activation
In contrast to the results above indicating that loss of PTEN
pression was associated with unfavorable clinical outcomes only in
LBCL with AKT hyperactivation, in the p-AKT-deficient training
bcohort (p-AKT−, cutoff: ≤30% which was approximate to the
ean p-AKT expression level, 33%), high Cyto-PTEN expression
yto-PTENhigh, cutoff: N40%; frequency: 36%) was associated with
ferior OS (P = .014) and PFS (P = .012), which was only significant
the GCB subtype (Figure 3A). In contrast, high Nuc-PTEN
pression (Nuc-PTENhigh, cutoff: N30%%; frequency: 5.2%) was
sociated with better OS and PFS in p-AKT− DLBCL cases
igure 3B), overall GCB-DLBCL cases, and the p-AKT− GCB-
LBCL subset.
Notably, Cyto-PTENhigh expression was associated with higher
ean levels of p-AKT (in both GCB and ABC), PI3K (P = .039),
yc (in GCB only), p21 (P = .0011), MDM2 (in both GCB and
BC), and p-STAT3 (in ABC only) expression at the protein level
igure 4A) but not at the mRNA level, and associated with both Bcl-
protein (P = .0021) and BCL2 mRNA (P = .0003) expression.
estricting the analysis in the p-AKT− DLBCL subset in which
ENhigh expression showed prognostic effect, Cyto-PTENhigh
pression remained to be associated with high Myc (an unfavorable
ognostic factor [36]) and p-AKT expression, significantly only in
e GCB subtype (Figure 4A). Nuc-PTENhigh expression was
sociated with higher mean levels of p-AKT and PI3K but not
yc expression, and the association with p-AKT expression was
gnificant only in the ABC subtype (Figure 4B).
In multivariate survival analysis adjusting for clinical parameters,
yto-PTENhigh remained as an unfavorable factor for PFS in
erall DLBCL and the p-AKT− DLBCL subcohort (P = .009; HR
77; 95% CI 1.15-2.72), whereas Nuc-PTENhigh was a favorable
ctor for PFS independent of clinical factors only in the overall
hort (P = .032; HR 0.37; 95% CI 0.15-0.92). After adding the
ctor of Mychigh in the Cox regression models, Cyto-PTENhigh
mained as an independent factor for unfavorable PFS only in p-
KT− DLBCL cases but not in the overall cohort, whereas Nuc-
ENhigh was a favorable factor for both OS (P = .043; HR 0.39;
% CI 0.16-0.97) and PFS in the overall cohort but not in the p-
KT− DLBCL subcohort (Table 3).
p-AKT− GCB-DLBCL p-AKT− GCB-DLBCL
B
A
)shtnom(emiT)shtnom(emiT
p-AKT− DLBCL
p-AKT− DLBCL p-AKT− DLBCL
Figure 3. Survival analysis for high levels of PTEN expression in DLBCL. (A) DLBCL patients with high cytoplasmic PTEN+ expression
(cutoff: N40%) had a significant poorer progression-free survival rate (PFS) compared with patients with low PTEN expression. The
adverse prognostic effect was only significant in DLBCL with no or low p-AKT expression (p-AKT−, cutoff: ≤30%), and GCB-DLBCL with
low p-AKT expression. (B) High nuclear PTEN+ expression (cutoff: N30%) was associated with trend of better PFS in DLBCL with no or
low p-AKT expression. The favorable prognostic effect was only significant in patients with no or low p-AKT expression.
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Figure 4. Biomarker expression analysis for high PTEN expression. (A) High cytoplasmic PTEN expression (N40%) was associated with
higher mean levels of p-AKT, Myc (in GCB only), PI3K, p-STAT3 (in ABC only), Bcl-2, and MDM2 expression. Only in DLBCL with no or low
p-AKT expression, high cytoplasmic PTEN expression was associated with higher mean levels of p-AKT and Myc expression. (B) High
nuclear PTEN expression (N30%) was associated with higher mean levels of p-AKT (in ABC only) and PI3K expression. Significant P values
are in bold.
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E
Figure 5. PTENmutation analysis in the DLBCL training cohort. (A) Proportions of classified point mutations. (B) PTEN mutation numbers
in the phosphatase domain (blue), C2 domain (red) and C-terminal tail. PTEN crystal figure is edited from Lee et al 1999; reference [41].
(C) Distribution of mutation numbers according to PTEN exons and codons. (D) PTENmutations in the C2 domain were associated with a
trend of higher mean cytoplasmic PTEN level but it was not significant. (E) Genes significantly differently expressed between wild-type
PTEN and mutated-PTEN groups in DLBCL with AKT hyperactivation.
584 PTEN expression and deficiency in DLBCL Wang et al. Neoplasia Vol. 20, No. 6, 2018Compared with the training cohort, the validation cohort had
higher frequency of Cyto-PTENhigh expression (52%) and
wer frequency of Nuc-PTENhigh expression (1.5%). As in the
aining cohort, in the validation cohort Cyto-PTENhigh
pression was associated with higher mean levels of p-AKTd Myc expression (Supplementary Figure S2A). In p-AKT−
ses (≤30% p-AKT expression), Cyto-PTENhigh expression was
sociated with trend of poorer survival, whereas Nuc-PTENhigh
as associated with trend of better survival. In contrast, in p-
KT+ cases (N30% p-AKT expression), Cyto-PTENhigh
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Table 4. Gene expression profiling analysis
PTENlow vs. PTENnot low in
GCB-DLBCL (FDRb0.01, fold N2)
PTENlow vs. PTENnot low in
ABC-DLBCL (FDRb0.01, fold N1.74)
Up-regulated Down-regulated Up-regulated Down-regulated
Signaling, receptors, B-cell
development and differentiation
PTEN, PTEN/PTENP1, STAP1, BLNK, FCRL1,
KLHL6, LPAR5, RGS1, RGS13, FCRL5, BANK1
PTEN, PKN2, RANBP9, MAP3K13, RGS13
Transcriptional regulation,
mRNA processing and regulation
INTS7, PABPC1, CBFB, EZH2, ZNF117,
IGF2BP3, HNRNPD, MYBL1
RFX7, ZEB1, HIF1A, TBL1XR1, OVOS/OVOS2,
SMCHD1, MBD4, TCF4, PRDM2
Cell cycle NIPBL, CASC5 GPSM2, DPY30/MEMO1, SMC1A, PTP4A1,
C7orf11, ZYG11B, MARK4, SFI1
Immune response, inflammation HLA-DMA/HLA-DMB, HLA-DPA1, HLA-DOA,
SERPINB9, HLA-DQB1, LYZ
POLR3E
Metabolism, ribosomes AMD1, RPL15, PGK1, SAMM50, CIRH1A C11orf54, AMD1, FUT8, RPL15, PDE7A,
DERA, PNPLA8, C21orf57, SLC16A1
Posttranslational modification,
protein degradation, transport
IDE, LRMP, CSE1L, UBE2G1, FBXO6 CCDC91, C18orf55, OSBPL8, USP1
Actin, cytoskeleton, cell adhesion,
extracellular matrix, motility
ANXA7, RABEP2, SYNE2, TMEM163,
FGD6, ENPP2, POSTN
ANXA7, RABEP2, KIAA1217, DMD
Unknown function ZDHHC11 FAM82B FAM82B, C12orf66, RP6-213H19.1, BAGE2/BAGE4
MUT-PTEN vs. WT-PTEN in
DLBCL (FDRb 0.05)
MUT-PTEN vs. WT-PTEN in p-AKThigh
DLBCL (FDRb 0.25)
Upregulated Downregulated Upregulated Downregulated
Signaling, receptors BOC, GPC4, GLRA3, PTPRF, C7orf16,
ACVR1C, UNC5C
DENND4C ACVR1C, ARHGAP22, OR10J1, CMTM6 IL6ST
Transcriptional regulation SOX10, DPPA4, TFAP2A NFATC3, ARHGEF10, GATA5, HSFY1/HSFY2
Cell growth and differentiation,
development
ADCY1, URG4, RABGAP1, AHRR
Immune response, inflammation PDCD6 MYD88 XPNPEP2
Metabolism FAM19A5 PGS1 NOX1, CPB1, PPP1R3E
mRNA processing and regulation,
protein folding, posttranslational
modification, degradation
C2orf30, AFF2, CUL7, RNF7,
USP46, PSMG4, ELAVL4, HERC6
ICMT UNKL, PAPOLG, RBM22, NXF2,
RNF8, RBMXL2
Transport, actin,
cytoskeleton, motility
MYO1C, DYNLRB1, STARD13, TTLL2, RHO KIF5B RAB9B, SLC17A4, ACTR3B
Cell adhesion, extracellular
matrix, ion channels
PCDHGB5, NLGN3, GJA3, ATP4B KCNA4, TMC2, PCDHGB5, KRTAP19-1, KCNIP4
IncRNA, pseudogene,
unknown function
ADCK2, PCA3, LOC283140, HYDIN/HYDIN2,
PRAMEF12, LOC100129175, C20orf12,
TMEM174, HEATR4, HSPC072/LINC00652,
C7orf45, LOC219731, HMCN2, LOC404266
LRPPRC, DCTN6 C16orf70, LOC728868, LRRN3, LOC151146,
C6orf195/LINC01600, HERV-V1,
FLJ37035, CECR9, TIGD1L, LOC100240734,
SMEK3P, C21orf37/LINC01549, TMEM220
Abbreviations: MUT-PTEN, PTEN mutated genotype; WT-PTEN, PTEN wild-type genotype; FDR, false discovery rate.
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uc-PTENhigh (only two cases) was associated with poorer PFS
upplementary Figure S2B). In the multivariate analysis, only
yto-PTENhigh expression in the p-AKT+ subcohort showed
end toward being an independent factor for better PFS (P =
85; HR 0.30; 95% CI 0.076-1.18).
TEN Gene Deletions and Mutations are Infrequent in
LBCL but are Independent Unfavorable Prognostic Factors
p-AKThigh DLBCL
To understand the mechanisms for PTEN deficiency in DLBCL,
EN gene deletion status was assessed in a total of 607 cases of
LBCL (359 plus 248 from the training and validation cohorts,
spectively), and PTEN mutation status was assessed in 368 cases
om the training cohort.
Totally 44 PTEN mutations were detected in 39 (10.6%) of 368
tients, including 23 (12.2%) patients with GCB-DLBCL and 16
.0%) patients with ABC-DLBCL. Of these, 8 (18%) mutations
ere in the regions encoding the phosphatase domain (corresponding
aa15-aa185, [46]) of the PTEN protein, 23 (52%) in the C2
main (aa185-aa351), and 12 (27%) in the C-terminal tail (aa351-403) (Figure 5, A–C). No correlation between PTEN mutation
d PTEN deletion or PTEN protein expression was observed,
though the expression levels of PTEN with C2 domain mutations
ere slightly increased (P = .38, Figure 5D).
A distinct GEP signature was identified for PTEN mutations
DR b 0.25, Figure 5E). Seven genes were down-regulated and
were up-regulated in the mutated-PTEN DLBCL subgroup
mpared with the wild-type PTEN DLBCL subgroup (FDR b 0.05,
able 4). Notably, PDCD6 which encodes programmed cell death 6,
calcium-binding protein required for T-cell receptor-, Fas-, and
ucocorticoid-induced cell death and having inhibitory function
wards PI3K/AKT/mTOR signaling [47], was up-regulated in the
utated-PTEN DLBCL group. Many genes related to neural
nction (such as BOC, GLRA3, UNC5C, GPC4, GLRA3, and
LGN3) and protein degradation (such as CUL7, RNF7, USP46,
d HERC6) were also up-regulated in the mutated-PTEN DLBCL
oup, whereas MYD88, which was recurrently mutated in primary
ntral nervous sytem (CNS) lymphoma [48], was downregulated.
e further compared mutated-PTEN DLBCL group with the wild-
pe PTEN DLBCL group in the p-AKThigh DLBCL subset. In the
utated PTEN subgroup, 43 genes were up-regulated whereas only
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tivation) was downregulated (Table 4). Up-regulated genes
cluded CNS-related genes (ADCY1 and ARHGEF10), genes
vovled in protein degradation, and PPP1R3E invovled in glycogen
etabolism.
Heterozygous or homozygous PTEN deletion (Figure 6A) was
ly present in 44 (12.3%) of 359 patients in the training cohort,
cluding 27 (61.4%) patients with GCB-DLBCL and 17 (38.6%)
atients with ABC-DLBCL. Only two of these cases had
mozygous deletion. Figure 6B depicted the case distribution of
TEN mutation and PTEN deletion in the training cohort.
TEN deletion cases overlapped with approximately 17.7% of
yto-PTEN− DLBCL cases, and 14.6% of Nuc-PTEN− DLBCL
ses. Similar frequency of PTEN deletion (heterozygous or
mozygous) was observed in the validation cohort (10.1%, 25
248 patients, including 4 patients [1.6%] who had homozygous
letion), which overlapped with approximately 13.6% of the
yto-PTEN − cases, and 15.9% of the Nuc-PTEN − cases
upplementary Figure S1C).
PTEN deletion was associated with lower mean levels of Cyto-
TEN expression in both the training and validation cohorts (P =
15 and P = .013, respectively; Figure 6C, and Supplementary
igure S1D). Only a trend of decrease in Nuc-PTEN expression was
sociated with PTEN deletion (P = .24) likely due to the low nuclear
TEN expression and small number of positive cases. Among cases
ith PTEN deletion, Cyto-PTEN+ expression status was associated
ith trend of better OS in the training cohort (P = .065, Figure 6C),
d significant better OS in the combined training and validation
hort (P = .031). Conversely, among Cyto-PTEN+ cases, PTEN
letion was associated significantly better OS (P = .02 in the training
hort and P = .006 in the combined cohort), despite the association
ith decreased Cyto-PTEN expression (P = .008 in the combined
hort).
The clinical features of patients with and without PTEN deletion/
utation in the training cohort are shown in Supplementary Tables
and S3. PTEN deletion was associated with age b60 years (P =
24) in ABC-DLBCL. PTEN mutation tended to be associated with
e ≥60 years (P = .078) in GCB-DLBCL and elevated LDH levels (P
.051) in ABC-DLBCL. Different from PTEN− expression status,
TEN deletion/mutation was not associated with decreased p-AKT,
I3K, survivin, Myc, p-STAT3, p21, or PD-L1 expression. However,
TEN deletion was associated with lower mean levels of MDM2 and
LIMP-1 expression (P = .01 and .027, respectively). We have shown
eviously that BLIMP-1 expression was associated with the ABC
btype [40].
Similarly with the prognostic effects associated with PTEN protein
ss, PTEN deletion and PTEN mutation were associated with trends
wards poorer survival in p-AKThigh DLBCL despite the small case
mbers (Figure 6D), although not in overall DLBCL (data not
own). The effect of PTEN deletion was stronger in the GCB
mpared with the ABC subtype. Moreover, multivariate analysis
justing for clinical factors showed that both PTEN mutation and
letion were independent prognostic factors for poorer OS and PFS
p-AKThigh DLBCL (Table 3).
Opposite to this observation in p-AKThigh DLBCL, in MYC-
arranged DLBCL cases, seven cases had PTEN deletion (heterozy-
us or homozygous) and significantly better survival (in the training
hort, P = .033 for OS and P = .064 for PFS; in the combined
aning and validation cohorts, P = .0097 for OS and P = .025 forFS; Figure 6E). Similar favorable effect of PTEN deletion was also
own in GCB-DLBCL with BCL2 rearrangement (P = .08 for OS in
e training cohort and P = .048 for OS in the combined cohorts).
onversely, among DLBCL cases harboring PTEN deletion, MYC
arrangement was associated with trend of better OS (P = .096 in the
aining cohort, P = .06 in the combined training and validation
hort; Figure 6F). However, multivariate analysis indicated that
TEN deletion was not a prognostic factor independent of clinical
ctors in MYC-rearranged patients. The better survival may be
tributable to the decreased Myc protein expression in these MYC-
arranged cases harboring PTEN deletion (P = .02 in the training
hort); we have shown previously that MYC-rearranged DLBCL
ses without Myc overexpression had superior survival [36]. In
dition, PTEN expression was positive in five of seven MYC-
arranged cases with PTEN deletion. Among cases with PTEN
letion, MYC rearrangement was associated with increased
toplasmic PTEN expression (P = .01, Figure 6G), which is similar
the association of Myc overexpression with cytoplasmic PTEN
pression (P = .0022, figure not shown).
oth Transcriptional and Post-transcriptional Mechanisms are
volved in Nuclear and Cytoplasmic PTEN Expression
egulation
The above data showed that PTEN genetic lesions only
ntributed to a small proportion of DLBCL with PTEN deficiency.
e further correlated PTEN expression to biologic data from our
evious studies [32,33,38] and found that loss of PTEN expression
as associated with TP53 mutation and IgA/IgG positive immuno-
enotypes (Table 1, Supplementary Table S1). Notably, previous
udies have shown that wild-type but not mutated p53 transactivates
TEN [49,50].
At the transcription level, we found that Nuc-PTEN negativity was
sociated with significantly lower PTEN mRNA expression (P =
054), more signficant in GCB-DLBCL (P = 0.0092) than in ABC-
LBCL (P = 0.081). Comparably, the association between PTEN
wnregulation and Cyto-PTEN− status was not significant (P =
065), with a stronger trend in ABC-DLBCL (P = 0.087) than in
CB-DLBCL (P = 0.36).
The lack of significant association of Cyto-PTEN expression with
TEN mRNA expression may suggest the important role of
sttranscriptional regulation in Cyto-PTEN expression. We further
tracted PTEN-targeting miRNA from miRNA profiling data and
und that Cyto-PTEN− status was associated with significantly
gher expression of several PTEN-targeting miRNAs, including
iR-106b-3p, miR-200c-5p, miR-486-5p, miR-141-5p, and miR-
0b-5p (Figure 7, A and B). When further analyzed in GCB/ABC
btypes, Cyto-PTEN negativity was associated with higher miR-
6, miR-130b, and miR-106b expression in GCB-DLBCL, and
ith higher miR-200c and miR-222 in ABC-DLBCL. In compar-
on, loss of Nuc-PTEN expression did not show correlations with
pression of most PTEN-targeting miRNAs except for higher miR-
6b-3p expression (P = .042, figure not shown). Interestingly,
sence of PD-L1 expression was also associated with significantly
gher levels of miR-106b-3p (P = .0088, Figure 7C) and miR-130b-
(P = .036, figure not shown) expression. These data may suggest
at posttranscriptional regulation including miRNA-mediated
igenetic mechanism played a significant role in regulating
toplasmic PTEN expression, whereas nuclear PTEN expression
as mainly regulated at the transcription level in GCB-DLBCL.
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ssociated with Low PTEN mRNA Expression
PTENmRNA expression showed much greater prognostic effect than
EN protein expression. Low PTENmRNA levels (PTEN-mRNAlow)
as associated with significantly poorer OS and PFS in overall DLBCL
d GCB-DLBCL, ABC-DLBCL, p-AKTlow, and p-AKThigh subsets
ith multiple cutoffs (Figure 7D, with a cutoff at 21st percentile).
Moreover, distinct GEP signatures were identified for low PTEN
RNA expression, but not for Cyto- or Nuc-PTEN protein
gativity. In GCB-DLBCL, up to 11,556 transcripts were up- or
wn-regulated in PTEN-mRNAlow patients compared with PTEN-
RNAnot low patients with a FDR threshold of 0.01. In ABC-
LBCL, 2,358 transcripts were differentially expressed between
TEN-mRNAlow and PTEN-mRNAnot low groups (FDR b 0.01).
hen use another cutoff at 50th percentile (median) for PTEN-
RNAhigh, a greater number of significant transcripts were
fferentially expressed between PTEN-mRNAhigh ABC-DLBCL
d other ABC-DLBCL patients (n = 10,361, FDRb0.01, data not
own). The spectrum of PTEN-mRNAlow genes in ABC-DLBCL
as similar with that in GCB-DLBCL, and both showed
wnregulation of genes involved in immune responses, B-cell
ceptor (BCR) signaling, gene expression, and metabolism, such as
wnregulation of HLA-DRB4, CD58, MS4A1/CD20, FCRL3,
SE1L, RPL15, and HNRNPA1. Notably, GEP analysis for AKT
peractivation also demonstrated downregulation of many genes
volved in immune responses, microenvironment, and metabolism
p-AKThigh GCB-DLBCL patients [34]. Two genes regulating
RNA turnover (PABPC1 and IGF2BP3) were downregulated in
th GCB and ABC subtypes of PTEN-mRNAlow DLBCL,
cluding IGF2BP3 which protects mRNAs against miRNA-
ediated degradation [51]. PTEN-mRNAlow gene signatures in
CB-DLBCL and in ABC-DLBCL with N2-fold and N1.74-fold
fferences, respectively, are shown in Figure 7E and Table 4.
iscussion
two large cohorts of DLBCL, PTEN expression was observed
ainly in the cytoplasmic compartments of the tumor cells (64–
% of cases); PTEN expression in the nucleus was less frequent
d at lower levels. PTEN cytoplasmic expression was more
equent and higher (by mean level) in the ABC compared with
CB subtype. The frequency of loss of cytoplasmic PTEN
pression observed in this study (25–36%) is comparable to
ose by other studies in DLBCL (31-37%) [28,30]. Complete loss
both cytoplasmic and nuclear PTEN expression was observed ingure 6. PTEN deletion and PTEN mutation analysis in the DLBCL trai
TEN deletion (right). Red signals: centromere 10; green signals: PTEN
LBCL and ABC-DLBCL cases, and their correlations with PTEN e
presents one patient; cases with PTEN deletion, mutation, PTEN lo
lors; cases without indicated abnormalities are shown in light blue or
ean level of cytoplasmic PTEN expression was significantly lower in pa
ne deletion. Among patients with heterozygous or homozygous PTEN
better overall survival rate (OS) in the training cohort. Among patient
sociated with significantly better OS. (D) PTEN deletion/mutation sh
tes in DLBCL cases with p-AKT overexpression. (E) In combined tra
gnificantly better OS in DLBCL cases withMYC gene rearrangement. (
as associated with better OS with borderline significance. (G) In MY
sociated with a significantly lower mean level of Myc expression.
sociated with a significantly higher mean level of PTEN cytoplasmic% of the training cohort and 11% of the validation cohort, which
as comparable to the frequency of complete loss of PTEN
pression reported in melanoma (25%) [25], and lower than those
some solid tumors, such as hepatocellular (57%), prostate (52%),
lorectal (48%) [25], glioblastoma (53%) [52], and triple-negative
east cancer (48%) [19]. Loss of cytoplasmic and/or nuclear PTEN
pression was associated with poorer clinical outcomes only in
LBCL with high p-AKT (Ser473) nuclear expression, which were
ainly manifested in the GCB subtype by univariate survival
alysis but were retained only in the ABC subtype by multivariate
alysis adjusting for clinical parameters. In contrast, in patients
ithout abnormal AKT activities, high cytoplasmic PTEN
pression was associated with poorer survival, which is also only
gnificant in the GCB subtype.
These findings may explain the inconsistent prognostic results in
LBCL by previous studies, and strongly suggest that the tumor-
ppressor function of PTEN is limited to the negative regulation of
e AKT signaling pathway. Supportingly, recent studies demon-
rated that the dependence of GCB-DLBCL on surface BCR density
d signaling is only in the presence of PTEN [53], and that most
KT inhibitor-sensitive DLBCL models did not express PTEN and
ere of GCB subtype; in contrast, PI3K inhibitor is selectively
fective in ABC-DLBCL through NF-κB inhibition [54]. These
ndings are consistent with that PTEN inhibits BCR-induced AKT
tivation in DLBCL [55,56], and intracellular PTEN levels
termine whether BCR signaling promotes cell death or cell survival
a differential regulation of PI3K/AKT and NF-κB pathways [57];
ss of the PTEN gene was preferentially detected in GCB-DLBCL,
d loss of PTEN expression defined a PI3K/AKT-dependent GCB-
LBCL [26,27,54]. On the other hand, studies also showed that
sides the well-known inhibition of PI3K/AKT via lipid phosphatase
tivity, PTEN has many other functions including those in the
cleus [8,58–60], negative regulation of central B-cell tolerance
eckpoints [61], and roles in B-cell homeostasis in the immune
stem [62]. Paradoxically, PTEN is required for both initiation and
aintenance of pre-B acute lymphoblastic leukemia cells, and loss of
TEN causes rapid cell death of transformed pre-B leukemia cells
1]. Such multi-directional functions of PTEN may explain the
posite prognostic effects of PTEN expression in AKT-hyperactive
LBCL and p-AKT− DLBCL cases, the lack of synergy between
TEN deletion and MYC rearrangement, and lack of distinct GEP
gnatures for PTEN expression and PTEN deletion.
As we have discussed in the previous review [43], loss/deficiency of
TEN expression can be attributed to genetic alterations andning cohort. (A) Representative FISH results for normal (left) and
gene. (B) Distribution of PTEN deletions and mutations in GCB-
xpression deficiency and p-AKT overexpression. Each column
ss, and p-AKT overexpression are highlighted in corresponding
white color (for negative or unknown status, respectively). (C) The
tients with PTEN gene deletion than that in patients without PTEN
deletion, patients with cytoplasmic PTEN expression had trend
s with positive PTEN cytoplasmic expression, PTEN deletion was
owed trends towards decreased progression-free survival (PFS)
ining and validation cohort, PTEN deletion was associated with
F) In DLBCL cases with PTEN deletion,MYC gene rearrangement
C rearranged DLBCL cases (training cohort), PTEN deletion was
In DLBCL cases with PTEN deletion, MYC rearrangement was
expression.
tr
PT
m
on
T
th
m
st
D
ex
Figure 7.miRNA profiling and gene expression profiling analysis in the training cohort. (A-B) Loss of cytoplasmic PTEN expression was
associated with significantly higher levels of miR-106b-3p, miR-200c-5p, miR-486-5p, miR-141-5p, and miR-130b-5p expression in DLBCL.
(C) Absence of PD-L1 expression was associated with significantly higher miR-106b-3p expression. (D) Low PTENmRNA expression was
associated with significantly worse progression-free survival (PFS) in GCB-DLBCL, ABC-DLBCL, and the p-AKThigh DLBCL subset. (E)
Genes significantly differently expressed between DLBCL groups with low PTEN mRNA expression and other cases (designated as
PTEN low and PTENnot low, respectively), and between DLBCL patients with wild-type PTEN (WT-PTEN) and mutated PTEN (MUT-PTEN).
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EN deletion (mostly heterozygous) and mutation as genetic
echanisms for PTEN deficiency and inactivation were observed in
ly approximately 11.3% and 10.6% of DLBCLs, respectively.
hese frequencies of PTEN gene alterations are much lower thanose in some solid tumors (homozygous deletion, up to 42.5%;
utation, up to 44%) [20,21,63], which is consistent with previous
udies in DLBCL and high-grade non-Hodgkin lymphoma [31,64].
istinct GEP signatures were identified for low PTEN mRNA
pression and PTEN mutations, which suggest that BCR signaling
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590 PTEN expression and deficiency in DLBCL Wang et al. Neoplasia Vol. 20, No. 6, 2018d B cell differentiation regulate PTEN expression at the
anscription level, and that PTEN is involved in CNS and immune
sponse regulation in addition to its function in AKT/mTOR
gnaling. It has been reported that PTEN loss was associated with
ain metastasis in melanoma patients [16].
We further explored the biological correlations and regulation
echanisms of PTEN expression. We surprisingly found that p-AKT
er473) nuclear expression and PTEN cytoplasmic expression were
sitively correlated in both training and validation cohorts, although
correlations were found between PTEN protein expression and
KT1 mRNA, nor between p-AKT protein expression and PTEN
RNA. As this was opposite to what one would expect (PTEN loss
ould correlate with increased p-AKT expression), we stained a
parate set of FFPE tissue samples for the entire DLBCL training and
lidation cohorts using another PTEN monoclonal antibody from
AKO (clone 6H2.1). However, again we found that PTEN
sitivity and high expression were associated with p-AKT expression
DLBCL samples (data not shown). Such surprising positive
nstead of negative) correlation between AKT and PTEN expression
as also found in breast cancer, melanomas, and urinary bladder
ncer by other studies [65–67]. Although paradoxical at the first
ance, these results may reflect the complex regulation network of
I3K/AKT/PTEN with divergent activating and inactivating [68]
echanisms as demonstrated by previous studies [54]. It is known
at phosphorylation at the Ser473 residue of AKT is mainly regulated
mTORC2 [69,70]; AKT activation in GCB-DLBCL is the
incipal consequence of tonic BCR signaling but AKT activation
ust not depend soly on the BCR signaling [53]. Notably, our results
4] showed that p-AKT (Ser473) expression was primarily associated
ith Myc and Bcl-2 expression (targets of mTORC2 and BCR
gnaling) in GCB-DLBCL (P b 0.0001), and with IL-6 expression in
BC-DLBCL (P = 0.0005), whereas the association with PI3K was
ther weak (P = 0.019 in the overall DLBCL cohort only). It is
ssible that the inhibitory effect of PTEN on AKT activation did not
minate the divergent mechanisms activating p-AKT (Ser473)
pression among DLBCL cases; these divergent mechanisms may
so indirectly up-regulate PTEN expression, since PTEN mRNA
pression showed correlation with BCR signaling gene signatures,
d Cyto-PTEN expression was associated with the ABC subtype,
hereas loss of PTEN was associated with IgA/IgG expression.
owever, as cytoplasmic PTEN expression was associated with
gnificantly decreased survivin expression (an indicator of AKT
nction in antiapoptosis) in ABC-DLBCL (Figure 1E), and we did
t examine the p-AKT (Thr308) expression, PTEN may still have a
gnificant role in repressing AKT function in DLBCL.
Moreover, the complexity between PTEN stability and function by
sttranslational modifications may also contributes to the positive
rrelation between p-AKT and PTEN IHC results. Earlier studies
dicated that phosphorylation of the PTEN’s C-terminal tail causes a
nformation change that stabilizes PTEN but at the same time
hibits its phosphatase activity and binding to the plasma membrane
]; PD-1 inhibits this stabilizing/inactivating phosphorylation [71].
nce the antibody we used detected total PTEN, it is possible that
e observed PTEN positivity also included stabilized phosphorylated
TEN (which has no tumor suppressor function), and PTEN
pression levels were not linearly correlated with PTEN function;
mmon mechanisms for the phosphorylation modification of PTEN
d AKT could exists. Notably, although PTEN mRNA expression
owed significantly favorable prognostic effect and striking GEPgnatures, such effect and distinct GEP signatures were lacking for
TEN protein expression in overall DLBCL. Therefore, the effect
d interpretation based on PTEN mRNA expression in DLBCL by
evious studies may deserve precaution.
In our DLBCL cohort, p-AKT expression was significantly
sociated with both PTEN and Myc expression; accordingly, Myc
pression also showed positive association with Cyto-PTEN
pression. MYC rearrangement and PTEN deletion showed
tagonistic rather than synergistic prognostic effect, but the case
mber was small. Whether the antagonistic effect resulted from
YC/PTEN gene structures is unknown; comparably lower Myc
pression and increased PTEN expression in these cases with
ncurrentMYC/PTEN abnormalities (Figure 6G) could be relevant.
otably, earlier functional studies demonstrated that Myc transcrip-
onally activates PTEN expression [72]; on the other hand, Myc
gatively regulates PTEN expression posttranscriptionally through
iRNAs [73,74]. Conversely, PTEN represses Myc expression by
hibiting PI3K/AKT signaling and transcriptional modulation
7,75]; scenario that PTEN deletion did not cooperate with Myc
tivation in tumorigenesis was also reported [76]. Again, these
ndings suggested the complexity of PTEN-involved molecular
twork.
In this study, loss of cytoplasmic PTEN expression was also
sociated with TP53 mutations and increased miRNA expression.
mong the PTEN-targeting miRNAs showing negative correlations
ith Cyto-PTEN expression, miR-106b, miR-222, miR-200c, and
iR-130b have been associated with poor prognosis [77–80].
argeting these overexpressing miRNAs could be a feasible strategy
increase PTEN expression in DLBCL.
Interestingly, we found that loss of Cyto-PTEN expression was
sociated with a lower mean level of PD-L1 expression in
LBCL, whereas PTEN deletion/mutation and expression of p-
KT, PI3K, or Nuc-PTEN had no association with PD-L1
pression. There was no correlation between PTEN and PD-L1
D274) mRNA expression. These data did not support the
nding in vitro that loss of PTEN function was associated with
creased PD-L1 expression [81]. However, in vivo studies found
at PTEN loss through PTEN deletion and mutation did not
crease PD-L1 expression in several mouse models. Because our
ta showed that both PD-L1 and Cyto-PTEN expression were
sociated with the ABC subtype and decreased miR-106b-3p and
iR-130b-5p expression, which have been shown to target PD-L1
pression in cancer cells [82,83], and PTEN-targeting miR-200c
3] is a key regulators of PD-L1 expression in acute myeloid
ukemia [84], we speculated that common regulators of PD-L1
rface expression and PTEN cytoplasmic expression possibly
nderlie the positive correlation between Cyto-PTEN and
embrane PD-L1 expression in this DLBCL cohort. Further-
ore, because PD-L1 expression was often associated with greater
kelihood of response to PD-1 blockade [85], our results may
ggest that Cyto-PTEN− DLBCL cases with lower PD-L1
pression would be less likely to respond to PD-1 blockade,
hich is consistent with the observation that PTEN loss was
sociated with inferior outcomes in patients with metastatic
elanoma who received PD-1 inhibitor therapy [86].
onclusions
summary, the prognostic significance of PTEN loss and
igh expression in de novo DLBCL treated with R-CHOP
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Neoplasia Vol. 20, No. 6, 2018 PTEN expression and deficiency in DLBCL Wang et al. 591pends on AKT activities. PTEN deletion and mutation may have
ited significance for poorer clinical outcome in DLBCL. PTEN
otein and PTEN mRNA expression showed totally different
ognostic effects and gene signatures in DLBCL. Our data suggest
at the PI3K/PTEN/AKT and Myc signaling pathways are
vergent rather than linear. Epigenetic and posttranslational
echanisms may play important roles in PTEN and PD-L1
pression.
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